NEA Partners 14, L.P.'s Net Worth
Estimate Recalculated Nov 8, 2024 09:38PM EST
Who is NEA Partners 14, L.P.
NEA Partners 14, L.P. does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Strongbridge Biopharma plc, INTERLEUKIN GENETICS INC, MULESOFT, INC, Oyster Point Pharma, Inc., APPIAN CORP, Mersana Therapeutics, Inc., Adaptimmune Therapeutics PLC, Loxo Oncology, Inc., CHAMPIONS ONCOLOGY, INC., Surface Oncology, Inc., Galera Therapeutics, Inc., Tracon Pharmaceuticals, Inc., SYNLOGIC, INC., Cerecor Inc., IMARA Inc., Casper Sleep Inc., and ZeroFox Holdings, Inc..
SEC CIK
NEA Partners 14, L.P.'s CIK is 0001551531
Past Insider Trading and Trends
2020 was NEA Partners 14, L.P.'s most active year for acquiring shares with 2 total transactions. NEA Partners 14, L.P.'s most active month to acquire stocks was the month of January. 2020 was NEA Partners 14, L.P.'s most active year for disposing of shares, totalling 2 transactions. NEA Partners 14, L.P.'s most active month to dispose stocks was the month of January. 2020 saw NEA Partners 14, L.P. paying a total of $0.00 for 60,000 shares, this is the most they've acquired in one year. In 2020 NEA Partners 14, L.P. cashed out on 60,000 shares for a total of $0.00, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
